Home › Immunoglobulin Light-chain Amyloidosis › NCT07850284

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age \>= 18 years
* Diagnosis of MM or AL based on IMWG diagnostic criteria
* Planned to start a new treatment within 14 days (+/-7 days)
* Able to provide written informed consent

Exclusion Criteria:

* Not able to give informed consent

About the study

This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether it can help in early identification of symptoms that may require clinical attention.

What is being tested

• Non-Interventional Study (other)

Sponsor: Mayo Clinic · Participants: 150 · Started: Aug 25, 2026

Contact the study team

• Clinical Trials Referral Office · Phone: 855-776-0015
• Sarah Aug · Phone: 507-538-1307

Official record on ClinicalTrials.gov — NCT07850284

Locations in the U.S.

Conditions

• Immunoglobulin Light-chain Amyloidosis
• Multiple Myeloma

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.